Operating Segments

6 Months Ended

Jun. 30, 2017

Note 10. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended June 30,
	2017			2016
Contract Revenue
Vaccines/BioDefense	$	990,971		$	3,160,050
BioTherapeutics		-			-
Total	$	990,971		$	3,160,050

Income (Loss) from Operations
Vaccines/BioDefense	$	197,270		$	734,120
BioTherapeutics		(1,574,261	)		(668,260	)
Corporate		(939,838	)		(1,075,818	)
Total	$	(2,316,829	)	$	(1,009,958	)

Amortization and Depreciation Expense
Vaccines/BioDefense	$	9,611		$	10,041
BioTherapeutics		8,077			10,564
Corporate		933			2,223
Total	$	18,621		$	22,828

Other Income (Expense), Net
Corporate	$	5,231		$	917,183

Share-Based Compensation
Vaccines/BioDefense	$	14,973		$	24,223
BioTherapeutics		22,827			30,985
Corporate		56,247			145,065
Total	$	94,047		$	200,273

	Six Months Ended June 30,
	2017			2016
Contract Revenue
Vaccines/BioDefense	$	2,321,855		$	5,791,037
BioTherapeutics		-			-
Total	$	2,321,855		$	5,791,037

Income (Loss) from Operations
Vaccines/BioDefense	$	333,870		$	1,052,111
BioTherapeutics		(2,601,816	)		(1,914,682	)
Corporate		(1,787,073	)		(2,053,092	)
Total	$	(4,055,019	)	$	(2,915,663	)

Amortization and Depreciation Expense
Vaccines/BioDefense	$	19,380		$	20,060
BioTherapeutics		17,644			20,996
Corporate		2,647			4,380
Total	$	39,671		$	45,436

Other Income (Expense), Net
Corporate	$	9,984		$	1,673,455

Share-Based Compensation
Vaccines/BioDefense	$	32,971		$	52,229
BioTherapeutics		72,597			65,817
Corporate		135,106			218,638
Total	$	240,674		$	336,684

	As of June 30, 2017		As of December 31, 2016
Identifiable Assets
Vaccines/BioDefense	$	783,821	$	1,297,986
BioTherapeutics		37,320		49,422
Corporate		5,952,481		8,919,698
Total	$	6,773,622	$	10,267,105